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Introduction
Multifunctional nanocarriers highly loaded with therapeutics and endowed with zero-premature leakage and controlled delivery features are expected to benefit millions of patients suffering from cancer worldwide. [1] [2] [3] Indeed, many cancer chemotherapeutic treatments still face low efficacies and failure despite tremendous financial investments of companies and governements. One of the main causes for this major societal concern is the lack of selectivity of anticancer drugs towards cancer tissues, leading to severe side effects on healthy tissues and eventually the death of patients. [4] This lack of spatial selectivity requires a high dose of drug to eradicate a tumor, which in turns limits the extent of the treatment that a patient can undergo before reaching a fatal dosage. Often, then, the treatment must be discontinued before the disappearance of the tumor, leaving the patient with little hope of remission. Additionally, cancer cells can become drug resistant after a prolonged treatement with a given drug. [5] As a result, the so-called nanomedicine has been an extensive research area aiming to design nanomaterials which could transport and deliver drugs, or other therapeutic agents, [6] selectively into tumors in order to decrease and preclude the side effects of chemotherapy, to decrease the dosage of drugs, and potentially transport several drugs to harness synergistic effects. [7, 8] Drug delivery nanosystems capable of transporting multiple drugs are emerging for the treatment of cancers. [9] [10] [11] [12] This strategy is based on the fact that chemotherapy was proved more effective for various pathologies when two drugs were combined. [13, 14] Combination chemotherapy using doxorubicin (DOX) and gemcitabine (GEM) simultaneously has produced better results than individual drugs, [15, 16] as the former causes both severe tissue necrosis and side effects, [17] and the latter has a short in-vivo half life (8-17 min) . [18] Due to different mechanisms of toxicity, this drug combination produces synergistic cancer cell killing, but remains significantly toxic for healthy tissues, hence justifying the need for a multi-
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3 drug delivery system. [19] DOX-loaded liposomes were clinically tested in combination with free GEM leading to promising results in patients. [20] Very few studies have reported the co-delivery of DOX and GEM in all areas of nanomaterial science. A polymeric carrier based on a copolymer of hydroxypropylmethacryl-amide encapsulated 6 weight percent (wt%) of each drug. [21] The system was applied in-vivo, but it should be noted that 25 % of the cargo was prematurely released after one day as the polymer entenglement could not prevent drug leakage. In 2014, vesicles of disulfide linked polyethyleneglycol-polylactic-acid (PEG-PLA) loaded with DOX and GEM, [19] and a prodrug design of a biodegrable PEG-PLA covalently linking DOX and GEM, [22] were applied in-vitro. Both studies demonstrated the potential of their carriers, nonetheless, the leakage at neutral pH was severe (20 and 40 % of GEM and DOX loaded-cargos respectively). [22] To date, a robust carrier co-delivering DOX and GEM drugs in high content has not been achieved.
Among recent developments in the area of smart nanomaterials, [3, [23] [24] [25] mesoporous silica nanoparticles (MSN) have attracted much attention as one of the most promising nanoplatforms for nanomedicine. [26] [27] [28] [29] [30] [31] [32] [33] [34] MSN are biocompatible nanomaterials [35, 36] and possess disctinctive characteristics such as their tunable porosity and particle size, versatile inner and outer surface chemistry, and capacity to transport and deliver various cargos make these scaffolds ideal drug delivery systems. [37, 38] Both molecular and supramolecular nanomachines have been designed with MSN to precisely control the release of guest molecules from their nanopores upon various stimuli including pH, [39, 40] one- [41, 42] and two-photon irradiation, [43] [44] [45] enzymes [46, 47] and redox processes. [48] Capping the pores of MSN was also carried out with inorganic particles, [49, 50] dendrimers, [51] and covalently-attached proteins. [52] [53] [54] However, few studies have described multi-drug delivery via MSN. Lin et al.
demonstrated the co-delivery of insulin and cyclic adenosine monophosphate in a sequential manner. [55] Insulin molecules were grafted on the MSN surface capped with a glucose-responsive system, while the pores were loaded with the second cargo. Palanikumar and coworkers very recently demonstrated than the loading capacity of MSN could reach 80 wt% through higher drug concentrations in loading solutions, [56, 57] unlike the typical 10 wt% threshold of previous reports. Building on this discovery, they loaded Gold nanoclusters (AuNCs) bioconjugated with proteins are highly attractive for bio-imaging as they are easily and reproducibly prepared, biocompatible, and have an intense red-NIR emission with high photo-stability, long fluorescence lifetime, and two photon excitation. [59] Commercially available bovine serum albumin (BSA) proteins were used to reduce gold salts and stabilize AuNCs composed of 25 gold atoms, affording highly biocompatible AuNC@BSA bioconjugates. [60, 61] The hydrodynamic diameter of AuNCs is typically below the kidney filtration threshold (~ 5.5 nm), which allows an efficient renal clearance after the intended biomedical application. [62] Controlling the size of AuNCs is also critical as it highly influences their fluorescence properties. [63] When compared to gold nanoparticles (AuNPs), [64] AuNCs-proteins have proved to be safer and more reliable imaging probes. [65] Interestingly, few reports have recently described the unique nuclei staining properties of AuNCs, [66, 67] which could allow the study of important biological processes such as mitosis. [67] This nuclei targeting is also the origin of several drug delivery studies, [68] [69] [70] [71] such as DOX delivery via AuNC@BSA combined with two-photon imaging. [72] AuNCs were also covalently grafted on non-porous silica NPs for cytosol imaging and reactive oxygen species detection via the quenching of the gold fluorescence, [73] however, AuNCs were not combined with MSN.
In this study, we describe a theranostic nanocomposite combining for the first time MSN and AuNCs encapsulating an unprecedented high amount of DOX (32 wt%) and GEM (40 wt%) drugs for pHtriggered autonomous multi-drug delivery. Negatively-charged AuNCs@BSA electrostatically-attached on ammonium-functionalized MSN to effectively block the pores (unlike two previous systems with covalently-attached MSN-BSA with the multi-step methods [53, 54] ), and provided a pH-responsiveness for cargo release and delivery. The interaction of DOX with BSA proteins was found to induce the formation of a highly loaded shell around GEM-loaded MSN NPs leading to exceptionally high payloads Figure 1 ). The uniqueness of the MSN-AuNC@BSA drug delivery system is summarized as follows: (1) The preparation of nanocarriers is straightforward as it requires non-covalent protein-MSN electrostatic interactions. (2) The system was however remarkably robust in blood serum with less than 3 % of drug leakage after one week thanks to the dense coating of BSA, which was also selected as it reduces the immunotoxicity of MSN. [74] (3) The dual loading of DOX and GEM had a total of 72 wt%, which is much higher than reported liposomes (7+3 wt%) [22] and polymers (6+6 wt%), [21] and forms an ideal drug combination for the treatment of ovarian and breast cancers. 
Results and Discussion

Preparation of MSN-AuNC@BSA nanocarriers
MSN were prepared in a typical sol-gel process involving the hydrolysis and condensation of tetraethoxysilane (TEOS) in a basic aqueous solution of cetyltrimethylammonium bromide (CTAB) template at 80ºC. Surface-functionalized amine-mesoporous NPs (MSN-NH 2 ) were then prepared by post-grafting of aminopropyl-triethoxysilane (APTES) on MSN-CTAB, which were then extracted. This strategy allowed a controlled functionalization of the NP surface (see Scheme S1). [75] Transmission electron microscopy (TEM) micrograph depicted the 2D hexagonal array of the pores (Figure 2A ), and
NPs sizes close to 150 nm, as confirmed by scanning electron microscopy (SEM, see Figure S1 ). The organized long-ranged mesoporosity was evidenced by small-angle X-ray diffraction (XRD) patterns in MSN and MSN-NH 2 with the intense peak at 2 degrees, as the satellites between 4 and 5 degrees ( Figure   S2 ). AuNC@BSA exhibited the absorption band of BSA (λ max = 390 nm) arising from aromatic amino acids (tryptophan, tryrosine), [71] as well as the AuNCs plasmon band (λ max = 496 nm, Fig S6) . The strong broad emission of the clusters from the red to the NIR (550 < λ em < 800 nm, λ max = 645 nm) ( Figure S6A ). [60] The conjugation of BSA to the nanoclusters was confirmed FTIR analysis with the primary amine scissoring N-H at 1538 cm -1 , the typical amide I C=O intense mode at 1659 cm -1 , as well as the N-H stretching mode at 3066 cm -1 ( Figure S7 ). [71] The MSN-AuNC@BSA nanocarrier was then designed and fully characterized. The design principle of the system is illustrated in Figure 1B Figure S8 ). Secondly, the DLS hydrodynamic diameter increase is shown in Figure 2C . Thirdly, nitrogen-sorption measurements performed before and after the formation of the AuNC@BSA shell around cargo-free MSN showed the disappearance of the type IV isotherm with a sharp drop of the Brunauer-Emmet-Teller (BET) surface area, from 863 to 162 m 2 .g -1 ( Figure 2D ). The diameter of the pores of silica NPs was centered at 2.3 nm (Figure S9) , [76] which is lower than that of the gold-protein bioconjugates. Fourthly, the coloration of capped NPs was obvious ( Figure 2E ) and the inductively coupled plasma-optical emission spectroscopy AuNC@BSA (see Figure 2G ).
Figure 2. TEM micrographs (A-B), DLS analyses (C), nitrogen sorption isotherms (D) of MSN-NH 2 (blue) and MSN-AuNC@BSA (red). Photographs of MSN-NH 2 and MSN-AuNC@BSA NPs powders (E). ICP-OES quantification of the gold content of MSN-AuNC@BSA, allowing the BSA content calculation (F).
Zeta potentials at pH 7 confirming the Au@BSA functionalization of cargo-free and cargo-loaded MSN-NH 2 (protonated at pH 7) (G).
Preparation of Dual-Loaded MSN-AuNC@BSA
The loading of various cargos in the MSN-AuNC@BSA nanocarrier was then investigated. In order to find out if the AuNC@BSA shell could act as a reservoir for DOX drugs, we investigated two methods for the loading of cargos into MSN. The MSN-drug aqueous mixture could be either centrifuged or not before the AuNC@BSA addition. In the first scenario, only DOX-loaded MSN are reacting with gold-proteins bioconjugates, which would minimize the amount of DOX potentially penetrating the AuNC@BSA shell, affording MSN-DOX-AuNC@BSA. The second scenario, however, would maximize the DOX loading both in the MSN pores and in the gold-proteins shell (MSN-DOX-AuNC@BSA-DOX, see Figure 1A ). In all cases, unbound AuNC@BSA were removed by selective centrifugation; cargo-loaded MSNAuNC@BSA could easily be precipitated and unbound cluster-protein conjugates were removed with the supernatant. Photographs presented in Figure 3A and B respectively display the successful increase of DOX payloads when the MSN pores and the AuNC@BSA shell are combined as drug reservoirs. It can
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10 also be seen that dispersed NPs (photographs on the left) are highly stable (for one month) and do not leak, as shown by the localized red color after centrifugation (photographs on the right). UV-visible spectroscopy clearly displayed the absorption band of DOX guests inside MSN-DOX-AuNC@BSA-DOX ( Figure 3C ), which possessed a much higher payload than MSN-DOX-AuNC@BSA (38 vs 12 wt%, calculated via analyses of drug supernatants: [m DRUG LOADED /(m NPs )]*100). As a control, we mixed BSA and DOX overnight in neutral aqueous medium, centrifuged and washed the resulting sample, and then analyzed it by TEM. We observed the formation of polydisperse 200 to 400 nm objects (see Figure S10) , and DLS depicted a broad size distribution centered at 365 nm ( Figure S11 ). The presence of a high content of DOX (29 wt%) was also monitored via uv-visible spectroscopy (λ max = 494 nm, Figure 3D wt% of HOE and 35 wt% of DOX (see Table S1 ). The loading of HOE/DOX is delineated alongside with GEM/DOX as it will be used as control to confirm the dual delivery of cargos (GEM cannot be visualized in cells). In-vivo studies described hereafter also necessitated the use of HOE to avoid the overlap of the 
Stability and pH-Triggered Release Studies
The stability of MSN-AuNC@BSA nanocarriers encapsulating various cargos was first studied. Both MSN-DOX-AuNC@BSA and MSN-DOX-AuNC@BSA-DOX nanocarriers were remarkably stable in
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12 neutral deionized water and blood serum for 2 to 3 weeks with less than 0.17 wt% of drug leakage (< 1 % of loaded cargos) ( Figure S21-24) . Similarly, GEM/DOX and HOE/DOX dual-loaded nanocarriers showed less than 2 % of loaded cargos leaking out in aqueous solution after two weeks ( Figure S23 ), 1 to 3 % and 1 to 7 % after 7 and 15 days in blood serum (Figure 4 and S24) . The slight leakage increase in the presence of serum results from the fact that this solution contains more molecules susceptible to interact with the electrostatically-assembled MSN-AuNC@BSA particles. Hence, the nearly zero leakages observed after few days in serum for dual-loaded NPs strongly suggest that both nanocarriers would remain stable in-vivo during the time necessary for their biomedical applications. At acidic pH, however, AuNCs@BSA become protonated (see zeta potentials in Figure S25 ) and thus detach from the MSN-NH 3 + ( = +25 mV, Figure 2G ) surface leading to the release of cargos ( Figure 1C ). uncommon, and given the interactions between BSA and many drugs, [78, 79] they could serve for nuclear-targeted drug delivery of specific therapeutics which would otherwise not reach this target.
Therefore, AuNC@BSA not only deliver a high content of DOX around MSN but also provide imaging multifunctionality to the drug delivery system.
Drug delivery experiments were then carried out in A549 cancer cells. MSN-DOX-AuNC@BSA-DOX were efficiently killing cancer cells, with nearly no cell survival at 100 g.mL -1 . Investigations of the first co-delivery of GEM and DOX drugs via MSN then lead to potent killings 100 g.mL -1 as well ( Figure 5F ), while at 25 g.mL -1 the DOX/GEM dual drug delivery caused a lower cell survival than DOX-loaded NPs thanks to the growth inhibitory effects of GEM. We additionally performed a control experiment to confirm the dual cargo delivery capability of our carrier by incubating MSN-HOEAuNC@BSA-DOX nanocarriers. As shown by Figure 6B , the co-delivery of DOX and HOE induces an intense nuclear staining in red and in blue, which supports the DOX and GEM co-delivery results. to accumulate in tumors due to the enhanced permeability and retention effect. In-vivo imaging was performed via red and blue channels which displayed the bioaccumulation of Hoe and AuNC mainly in the tumor, and partly in the liver and in kidneys (see Figure 7) . Afterwards, all mice were euthanized, all organs were collected and fluorescence analyses were carried via the Maestro 2 imaging system. Once again, the fluorescence of AuNCs and Hoe was mainly detected in the tumor, and also in the liver and in kidneys (Figure 8 ), which clearly demonstrated the potential of the MSN-AuNC@BSA for tumor imaging. 
Conclusions
We have described the first co-delivery of the gemcitabine and doxorubicin anticancer drugs via an inorganic nanocarrier. Our design involved the mesoporous silica nanoparticles encapsulating a high
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18 content of gemcitabine (40 wt%) and electrostatically-gated with a gold cluster-protein shell acting as a reservoir for doxorubicin (32 wt%) . Unlike the few reports on liposome and polymeric nanocarriers, our vehicle was remarably robust since less than four percent of loaded drugs leaked out after one week in blood serum, and the drug payloads were four times higher. This smart nanocarrier autonomously opened at lysosomal pH to deliver the drug combination in cancer cells with a nearly total cell killing. Besides, conversely to most MSN drug delivery systems, these uniform nanocarriers can be simply prepared via mixing, harnessing diagnostic and therapeutic features of the MSN and AuNCs in a multifunctional theranostic nanoplatform. Furthermore, the strong fluorescence of the AuNC@BSA was found almost exclusively in the tumor, and slightly in the liver and kidneys, with the same trend with Hoe cargos. The designed nanocarrier thus combined the unique features of mesoporous silica and AuNCs for the straightforward preparation of a theranostic nanomedical device endowed with tumor diagnosis, especially releavant for the treatment of ovarian and breast cancers via combination therapy.
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